PA
ENGN icon

Perceptive Advisors’s enGene Therapeutics ENGN Stock Holding History

Perceptive Advisors’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.7M Sell
5,827,506
-41,570
-0.7% -$370K 0.78% 29
2025
Q4 		$53M Buy
5,869,076
+3,771,840
+180% +$30.2M 0.94% 32
2025
Q3 		$14.3M Buy
+2,097,236
New +$9.56M 0.41% 49
2024
Q3 		– Sell
-800,000
Closed -$7.54M – 113
2024
Q2 		$7.54M Sell
800,000
-198,888
-20% -$2.55M 0.18% 70
2024
Q1 		$16.9M Buy
+998,888
New +$12.2M 0.3% 66

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Perceptive Advisors's ENGN Position: Q1 2026 in Review

Perceptive Advisors reduced its enGene Therapeutics (ENGN) stake by 0.71% in Q1 2026, selling an estimated $370K and leaving 5,827,506 shares worth $39.7M. The position accounts for 0.78% of the portfolio, ranked #29.

Perceptive Advisors first reported a position in ENGN in Q1 2024 and has held it in 5 quarters since. The position peaked at $53M in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Perceptive Advisors held 5,827,506 shares of enGene Therapeutics worth $39.7M as of Q1 2026.
  • Perceptive Advisors sold 41,570 enGene Therapeutics shares in Q1 2026, an estimated $370K.
  • enGene Therapeutics made up 0.78% of Perceptive Advisors's portfolio in Q1 2026, its #29 holding.
  • Perceptive Advisors first reported a position in enGene Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Perceptive Advisors's enGene Therapeutics position peaked at $53M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.